Changes in HT prescriptions in Australia since 1992

Nathan J. Coombs, John Boyages*

*Corresponding author for this work

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Hormone therapy (HT) use in Australia and America increased from 1992. However, recent studies have highlighted its risks for breast and endometrial cancer, thromboembolic disorders and cardiovascular disease. One of these studies (the Women’s Health Initiative [WHI] trial) was terminated prematurely because of excess adverse cardiovascular events and invasive breast cancer with oestrogen and progestogen. The publicity generated increased public awareness of the risks of HT. This has been further heightened with the publication of the Million Women study. However, the recently published oestrogen only HT (indicated only for women with a hysterectomy because of the risk of endometrial hyperplasia and uterine cancer) arm of the WHI trial suggested that this formulation may reduce the risk of
breast cancer.
Original languageEnglish
Pages (from-to)697-698
Number of pages2
JournalAustralian Family Physician
Volume34
Issue number8
Publication statusPublished - Aug 2005
Externally publishedYes

Keywords

  • Adult
  • Australia
  • Drug Prescriptions
  • Drug Utilization
  • Estrogen Replacement Therapy
  • Female
  • Humans
  • Middle Aged
  • Practice Patterns, Physicians'
  • Journal Article
  • Research Support, Non-U.S. Gov't

Fingerprint Dive into the research topics of 'Changes in HT prescriptions in Australia since 1992'. Together they form a unique fingerprint.

Cite this